- Adalimumab, sold
under the
brand name
Humira and others, is a disease-modifying
antirheumatic drug and
monoclonal antibody used to
treat rheumatoid arthritis...
- was 74, and rank 89 on the 2024 list. The company's
primary product is
Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total), administered...
-
discussions regarding the
applicability of the
royalty offset provisions for
Humira" (Adalimumab) with
Abbott Laboratories in the High
Court of London. In December...
-
Humira Saqib (Dari: حمیرا ثاقب; born 1980) is an
Afghan journalist and women's
human rights activist.
Through her
writings in the
magazine Negah-e-Zan...
-
antitrust implications. In In re
Humira, 465 F.Supp.3d 811 (N.D. Ill. 2020), a
class of third-party
payors for
Humira argued that
pharmaceutical company...
- (PDF) from the
original on
September 19, 2020.
Retrieved June 9, 2020. "
Humira EPAR".
European Medicines Agency (EMA).
Archived from the
original on February...
- Pharma. May 1, 2019.
Retrieved July 11, 2022. "AbbVie,
nearing the end of
Humira's historic run,
scoops up a
struggling Allergan for $63B".
Fierce Pharma...
-
factor (TNF)-alpha
inhibitors like
infliximab (Remicade) and
adalimumab (
Humira) have
shown promise for some, but they
should probably be
considered a third-line...
- Switzerland. In July 2023,
Sandoz launched a
biosimilar version of
AbbVie Inc's
Humira,
under the label, Hyrimoz. In
September 2023,
Novartis announced that the...
- 16, 2020.
Retrieved December 25, 2019.
Bulik BS (March 2016). "AbbVie's
Humira, Pfizer's
Lyrica kick off 2016 with
hefty TV ad spend". FiercePharma. Archived...
